# Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

> **NCT04451200** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 82 (estimated)

## Conditions studied

- Acute Leukemia
- Mielodysplasic Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Busulfan Injection

## Key facts

- **NCT ID:** NCT04451200
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-11
- **Primary completion:** 2023-11
- **Final completion:** 2028-12
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04451200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04451200, "Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04451200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*